Story perspectives

Oxford Study Tests AI for Personalized Prostate Cancer Treatment

11/3/2025

31 2

Summary

Story summary

University of Oxford leads Vanguard Path study to assess AI's ability to improve prostate cancer treatment decisions.
The Vanguard Path study, funded by Prostate Cancer UK, will test the ArteraAI Prostate Biopsy Assay on biopsy samples from diagnosed patients.
It will take place at three National Health Service sites and compare AI predictions with outcomes.
If successful, the study could lead to more personalized treatment plans for prostate cancer.

1 of 1

Story summary

University of Oxford leads Vanguard Path study to assess AI's ability to improve prostate cancer treatment decisions.
The Vanguard Path study, funded by Prostate Cancer UK, will test the ArteraAI Prostate Biopsy Assay on biopsy samples from diagnosed patients.
It will take place at three National Health Service sites and compare AI predictions with outcomes.
If successful, the study could lead to more personalized treatment plans for prostate cancer.